Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12630-023-02658-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letter to editor regarding "bone modifying agents in breast cancer patients as adjuvant therapy and prevention of cancer treatment-induced bone loss (CTIBL): Evaluation of risk of medication-related osteonecrosis of the jaw (MRONJ)".
Support Care Cancer
October 2024
Department of Medicine, Oncology Unit, "SS Antonio E Biagio E C. Arrigo" Hospital, 15121, Alessandria, Italy.
Reply to Ganda and colleagues' Letter to the Editor regarding "Defining the Key Clinician Skills and Attributes for Competency in Managing Patients with Osteoporosis and Fragility Fractures".
J Bone Miner Res
November 2024
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1825 University Blvd., Birmingham, AL 35294, United States.
Defining the key clinician skills and attributes for competency managing patients with osteoporosis and fragility fractures.
J Bone Miner Res
November 2024
Menzies Institute for Medical Research and Faculty of Health, University of Tasmania, Hobart, Tasmania 7000, Australia.
Systemic effects of hypophosphatasia characterization of two novel variants in the gene.
Front Endocrinol (Lausanne)
January 2024
Instituto de Investigación Biosanitaria de Granada, Granada, Spain.
Introduction: Hypophosphatasia (HPP) is an inborn metabolic error caused by mutations in the ALPL gene encoding tissue non-specific alkaline phosphatase (TNSALP) and leading to decreased alkaline phosphatase (ALP) activity. Although the main characteristic of this disease is bone involvement, it presents a great genetic and clinical variability, which makes it a systemic disease.
Methods: Patients were recruited based on biochemical assessments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!